Ciclesonide nasal

DRUG2 trials

Sponsors

AstraZeneca, McGill University Health Centre/Research Institute of the McGill University Health Centre

Conditions

COVID 19Hay FeverRhinitis, Allergic, Perennial

Phase 2

Inhaled Ciclesonide for Outpatients With COVID19

TerminatedNCT04435795

McGill University Health Centre/Research Institute of the McGill University Health CentreCOVID 19

Start: 2020-09-15End: 2021-07-08Updated: 2022-06-10

Phase 3

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

CompletedNCT00658918

AstraZenecaHay Fever, Rhinitis, Allergic, Perennial

Start: 2004-09-30End: 2005-11-30Updated: 2016-12-02

Related Papers

Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial

BMJ2021-11-0273 citations